Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences
Retrieved on:
Thursday, September 10, 2020
Health, Infectious diseases, Other Health, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Biology, Natural sciences, Proteins, Immunology, Contingent value rights, Corporate finance, Valuation, Ligand, Antibody, xCella Biosciences, Taurus Biosciences, OmniAb®, Ligand Pharmaceuticals
Ligand acquired xCella Biosciences, Inc. for $7 million in cash plus potential earnouts, and acquired Taurus Biosciences LLC for $5 million in cash plus non-transferable contingent value rights (CVRs).
Key Points:
- Ligand acquired xCella Biosciences, Inc. for $7 million in cash plus potential earnouts, and acquired Taurus Biosciences LLC for $5 million in cash plus non-transferable contingent value rights (CVRs).
- Ligand evaluated multiple public and private platforms to acquire in order to continue the expansion of the OmniAb platform and determined xCella and Taurus represented the best fit and opportunity.
- Bringing the capabilities and intellectual property of these two companies into Ligand will strengthen our antibody discovery capabilities, in particular our OmniChicken platform.
- Ligands OmniAb technology platform is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies.